Cagrilintide is an amylin analog, while semaglutide is a GLP-1 receptor agonist
15 mg Highest Labeled Weekly Dose Fifteen milligrams is the maximum labeled weekly tirzepatide dose
Reasons to increase your dose include plateau in weight loss after an initial response, inadequate appetite suppression despite consistent use, or sufficient tolerance to previous doses without significant nausea or constipation
The difference in beneficial effects on tobacco use disorder-related health outcomes was the highest between semaglutide and insulin, but the beneficial effects of other GLP-1RAs were only slightly, albeit significantly, lower than those of semaglutide
If you are considering, or have been prescribed, tirzepatide, its important to be informed about potential side effects and how we can support you throughout your treatment